This poor outcome was also evident for the rare STAG2-mutant cases that were not diagnosed as AML-MR because of competing classifying mutations (e.g., NPM1 and/or CEPBA, Supplementary Fig. 10A, B). This evidence concerns the gene STAG2 and acute myeloid leukemia.